Sleep: Another benefit of regular sleep

A large observational study has found that irregular sleep-wake patterns are associated with a higher risk of overall mortality, and also mortality from cancers and cardiovascular disease.
  1. Tianyi Huang  Is a corresponding author
  1. Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, United States
  2. Division of Sleep Medicine, Harvard Medical School, United States

Benjamin Franklin’s famous quotation – “Early to bed and early to rise makes a man healthy, wealthy, and wise” – underscores the importance of sleep-wake patterns to our health and well-being. Of all the phenomena that are influenced by the 24 hour light-dark cycle, the sleep-wake cycle is the best known, but many other biological processes central to health are also influenced. However, empirical evidence about the impact that disruptions to sleep-wake patterns have on human health remains sparse and is mostly limited to studies on shift workers, despite an increase in other forms of disruption (notably higher levels of artificial light at night and increased use of mobile media in bed).

In recent years, an increasing number of studies have looked at the impact of sleep regularity (and irregularity) on aspects of health besides sleep quantity and quality, often made possible by the availability of wearable technology that is able to monitor rest-activity cycles in large numbers of people. Studies have found evidence that sleep irregularity is associated with a higher incidence of obesity (Patel et al., 2014), depression (Fang et al., 2021), cardiovascular disease (Huang et al., 2020) and other chronic disease outcomes.

Now, in eLife, Matthew Pase, Andree-Ann Baril and colleagues – including Lachlan Cribb, Ramon Sha and Stephanie Yiallourou, all of Monash University, as joint first authors – go one step further by linking sleep regularity with all-cause and cause-specific mortality in a large UK population (Cribb et al., 2023). Between 2013 and 2015, a total of more than 106,000 participants in the UK wore a watch-like device called an accelerometer over seven consecutive days. Based on the signals from this device it was possible to tell when the participants were asleep, sedentary, or active. Cribb et al. then derived a novel metric called the Sleep Regularity Index (SRI) to quantify day-to-day consistency in sleep-wake schedules. This metric is an estimate of how likely it is that a person is in the same state (that is, either awake or asleep) at any two time points 24 hours apart, with higher SRI values indicating higher sleep regularity. The researchers also noted how many of the participants subsequently died (via data from the UK national death register).

Over a median follow-up of 7.1 years, some 3,010 participants died, with 1,701 of these deaths being due to cancers and 616 being due to cardiovascular disease. Compared with those who had a medium SRI value, the top 5% (that is, the most regular sleepers) had 10% lower all-cause mortality, and the bottom 5% (that is, the most irregular sleepers) had 53% higher mortality. The association appeared nonlinear, with stronger associations observed for the increased mortality with more irregular sleep. Similar nonlinear patterns were observed when Cribb et al. examined cancer mortality and cardiovascular disease mortality separately.

The work by Cribb et al. is consistent with recent studies on sleep regularity and mortality from the US and Japan, although these findings are based on a smaller sample size (Chung et al., 2023a) or on self-reported sleep regularity (Omichi et al., 2022). Other studies found that sleep regularity was a stronger predictor for mortality than sleep duration or sleep apnea (Chung et al., 2023b; Windred et al., 2023). Interestingly, a genome-wide association study for sleep traits (Jones et al., 2019) reported a heritability estimate of 2.8% for sleep regularity, compared with 19.0% for sleep duration and 22.3% for fragmented sleep: this suggests that it may be easier to modify sleep regularity via interventions than it would be to modify other sleep traits because sleep regularity is less genetically determined.

Promoting sleep regularity is not a new idea in the area of ‘sleep hygiene’, and encouraging regular sleep schedules is also an essential component in cognitive behavioral therapy for insomnia (Sletten et al., 2023). From the behavioral perspective, promoting sleep regularity may also enhance the time-of-day effect of other behaviors, such as time-restricted eating and exercise. However, promoting sleep regularity for broader health promotion and disease prevention has not been tested in intervention studies and requires additional evidence from future investigations.

In summary, the study by Cribb et al. adds to the emerging evidence for the potential benefits of sleep regularity on chronic disease risk and mortality. The findings, in conjunction with prior evidence, provide a strong foundation to answer the following question: would public health interventions to improve sleep regularity causally lead to reductions in chronic disease and premature deaths at the population level?

References

Article and author information

Author details

  1. Tianyi Huang

    Tianyi Huang is in the Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, United States, and the Division of Sleep Medicine, Harvard Medical School, Boston, United States

    For correspondence
    tih541@mail.harvard.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8420-9167

Publication history

  1. Version of Record published: December 1, 2023 (version 1)

Copyright

© 2023, Huang

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 802
    views
  • 60
    downloads
  • 0
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Tianyi Huang
(2023)
Sleep: Another benefit of regular sleep
eLife 12:e94131.
https://doi.org/10.7554/eLife.94131
  1. Further reading

Further reading

    1. Computational and Systems Biology
    2. Epidemiology and Global Health
    Javier I Ottaviani, Virag Sagi-Kiss ... Gunter GC Kuhnle
    Research Article

    The chemical composition of foods is complex, variable, and dependent on many factors. This has a major impact on nutrition research as it foundationally affects our ability to adequately assess the actual intake of nutrients and other compounds. In spite of this, accurate data on nutrient intake are key for investigating the associations and causal relationships between intake, health, and disease risk at the service of developing evidence-based dietary guidance that enables improvements in population health. Here, we exemplify the importance of this challenge by investigating the impact of food content variability on nutrition research using three bioactives as model: flavan-3-ols, (–)-epicatechin, and nitrate. Our results show that common approaches aimed at addressing the high compositional variability of even the same foods impede the accurate assessment of nutrient intake generally. This suggests that the results of many nutrition studies using food composition data are potentially unreliable and carry greater limitations than commonly appreciated, consequently resulting in dietary recommendations with significant limitations and unreliable impact on public health. Thus, current challenges related to nutrient intake assessments need to be addressed and mitigated by the development of improved dietary assessment methods involving the use of nutritional biomarkers.

    1. Epidemiology and Global Health
    Caroline Krag, Maria Saur Svane ... Tinne Laurberg
    Research Article

    Background:

    Comorbidity with type 2 diabetes (T2D) results in worsening of cancer-specific and overall prognosis in colorectal cancer (CRC) patients. The treatment of CRC per se may be diabetogenic. We assessed the impact of different types of surgical cancer resections and oncological treatment on risk of T2D development in CRC patients.

    Methods:

    We developed a population-based cohort study including all Danish CRC patients, who had undergone CRC surgery between 2001 and 2018. Using nationwide register data, we identified and followed patients from date of surgery and until new onset of T2D, death, or end of follow-up.

    Results:

    In total, 46,373 CRC patients were included and divided into six groups according to type of surgical resection: 10,566 Right-No-Chemo (23%), 4645 Right-Chemo (10%), 10,151 Left-No-Chemo (22%), 5257 Left-Chemo (11%), 9618 Rectal-No-Chemo (21%), and 6136 Rectal-Chemo (13%). During 245,466 person-years of follow-up, 2556 patients developed T2D. The incidence rate (IR) of T2D was highest in the Left-Chemo group 11.3 (95% CI: 10.4–12.2) per 1000 person-years and lowest in the Rectal-No-Chemo group 9.6 (95% CI: 8.8–10.4). Between-group unadjusted hazard ratio (HR) of developing T2D was similar and non-significant. In the adjusted analysis, Rectal-No-Chemo was associated with lower T2D risk (HR 0.86 [95% CI 0.75–0.98]) compared to Right-No-Chemo.

    For all six groups, an increased level of body mass index (BMI) resulted in a nearly twofold increased risk of developing T2D.

    Conclusions:

    This study suggests that postoperative T2D screening should be prioritised in CRC survivors with overweight/obesity regardless of type of CRC treatment applied.

    Funding:

    The Novo Nordisk Foundation (NNF17SA0031406); TrygFonden (101390; 20045; 125132).